Last reviewed · How we verify

Treatment prior to tumor-specific T-cell infusion therapy — Treatment Landscape & Competitive Intelligence

Treatment prior to tumor-specific T-cell infusion therapy (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Treatment prior to tumor-specific T-cell infusion therapy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Treanda BENDAMUSTINE Baxter Alkylating Drug Histone deacetylase 6 2008-01-01
Vepesid etoposide Bristol-Myers Squibb K.K. Topoisomerase Inhibitor [EPC] DNA topoisomerase 2-alpha 1983-01-01
Cytoxan (Lyophilized) cyclophosphamide Baxter Alkylating agent Tumor cell DNA 1959-01-01
Etoposid Etoposid University of Ulm Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2, Multidrug resistance-associated protein 6
Bendamustin Bendamustin Meir Medical Center Histone deacetylase 1, Histone deacetylase 10, Histone deacetylase 2
Cyclophosphamid Cyclophosphamid Zhejiang University Cytochrome P450 3A4

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Baxter · 3 drugs in Treatment prior to tumor-specific T-cell infusion therapy
  2. Bristol-Myers Squibb K.K. · 1 drug in Treatment prior to tumor-specific T-cell infusion therapy
  3. Meir Medical Center · 1 drug in Treatment prior to tumor-specific T-cell infusion therapy
  4. University of Ulm · 1 drug in Treatment prior to tumor-specific T-cell infusion therapy
  5. Zhejiang University · 1 drug in Treatment prior to tumor-specific T-cell infusion therapy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Treatment prior to tumor-specific T-cell infusion therapy:

Cite this brief

Drug Landscape (2026). Treatment prior to tumor-specific T-cell infusion therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-prior-to-tumor-specific-t-cell-infusion-therapy. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing